India’s Pricing Authority Cuts Prices On Two Sanofi Insulin Products
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's pharmaceutical pricing watchdog, the National Pharmaceutical Pricing Authority, has increased prices of 186 formulation brands while slashing prices of Lantus/Solostar (insulin glargine injection) and monocomponent insulin, the two key insulin drugs from French drug maker Sanofi-Aventis, the NPPA announced Aug. 7
You may also be interested in...
India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus
MUMBAI - For nearly a decade, the world's fourth-largest drug maker, Sanofi-Aventis, has had a free play in India in marketing its world-famous insulin brand Lantus, the only long-acting basal insulin, widely prescribed for its ability to slowly release insulin into the body. Now that could change as two large Indian players, Wockhardt and Biocon, are looking at chipping away some of this lucrative and growing market through their own brand launches
India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus
MUMBAI - For nearly a decade, the world's fourth-largest drug maker, Sanofi-Aventis, has had a free play in India in marketing its world-famous insulin brand Lantus, the only long-acting basal insulin, widely prescribed for its ability to slowly release insulin into the body. Now that could change as two large Indian players, Wockhardt and Biocon, are looking at chipping away some of this lucrative and growing market through their own brand launches
India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus
Biocon launched its brand Basalog in 10 ml and 3 ml vials, and Wockhardt launched Glaritus (glargine) in reusable and disposable pen-delivery devices.